Page 113 - 《中国药房》2026年5期

“BRAND”药学服务模式用于驱动基因阳性晚期 NSCLC 患者的

实践研究
Δ

#
＊
郁件康 ，龚 伟，石金芳，唐 婕，龚银华（苏州大学附属第一医院药学部，江苏 苏州 215000）
中图分类号 R95 文献标志码 A 文章编号 1001-0408（2026）05-0655-05
DOI 10.6039/j.issn.1001-0408.2026.05.18

摘 要 目的 构建针对驱动基因阳性晚期非小细胞肺癌（NSCLC）患者的“BRAND”药学服务模式，为临床开展精准化、个体化
肿瘤药学服务提供理论与实践参考。方法 根据纳排标准收集2023年1月至2024年5月在我院呼吸与危重症医学科住院的患者
100例，将患者随机分为对照组和干预组，每组50例。对照组接受常规药学服务，干预组接受“BRAND”药学服务（收集患者基本
信息、回顾疾病治疗相关信息、精准用药评估、明确下一步个体化药学服务方案、实施用药指导及随访管理）。每3周为1个周期，
研究共持续4个周期。比较干预前后两组患者的用药依从性、生活质量、实验室检验指标、药物相关不良事件发生率和患者满意
度，进行效果评价。结果 干预12周后，与对照组比较，干预组患者的用药依从性、认知功能、社会功能、满意度均显著提高（P＜
0.05），疲乏、便秘的严重程度及药物相关不良事件发生率均显著降低（P＜0.05），实验室检验指标差异无统计学意义（P＞0.05）。
结论 “BRAND”药学服务模式可有效提高驱动基因阳性晚期NSCLC患者的用药依从性、改善其生活质量，为临床药师开展标准
化、高质量的药学服务提供了可行路径。
关键词 “BRAND”药学服务模式；驱动基因阳性；晚期；非小细胞肺癌；药学服务

Practical study on the application of “BRAND” pharmaceutical care model in advanced NSCLC patients
with positive driver genes
YU Jiankang，GONG Wei，SHI Jinfang，TANG Jie，GONG Yinhua（Dept. of Pharmacy， the First Affiliated
Hospital of Soochow University， Jiangsu Suzhou 215000， China）

ABSTRACT OBJECTIVE To establish a “BRAND” pharmaceutical care model for advanced non-small cell lung cancer
（NSCLC） patients with positive driver genes， providing theoretical and practical references for the clinical implementation of
precise and individualized oncology pharmaceutical care. METHODS One hundred patients admitted to the department of
pulmonary and critical care medicine in our hospital from January 2023 to May 2024 were collected meeting the inclusion and
exclusion criteria. Patients were randomly divided into control group and intervention group， with 50 patients in each group. The
control group received routine pharmaceutical care， while the intervention group received pharmaceutical care under the “BRAND”
model （collecting patients’ basic information， reviewing disease treatment-related information， conducting precise medication
assessments， formulating individualized pharmaceutical care plans for the next steps， and implementing medication guidance and
follow-up management）. The study was conducted in a 3-week cycle for a total of 4 cycles. The medication compliance， quality of
life， laboratory test indicators， incidence of drug-related adverse events and satisfaction of patients in both groups were compared
before and after the intervention to evaluate the effects. RESULTS After 12 weeks of intervention， compared with the control
group， the medication compliance， cognitive function， social function and satisfaction of patients in the intervention group were
improved significantly （P＜0.05）； the severity of fatigue and constipation and the incidence of drug-related adverse events were
significantly reduced （P＜0.05）， and there was no statistically significant difference in laboratory test indicators （P＞0.05）.
CONCLUSIONS The “BRAND” pharmaceutical care model can effectively improve the medication compliance of patients with
advanced NSCLC with positive driver genes and improve their quality of life. This study can provide a feasible path for clinical
pharmacists to carry out standardized and high-quality pharmaceutical care.
KEYWORDS “BRAND” pharmaceutical care model； positive driver gene； advanced stage； non-small cell lung cancer；
pharmaceutical service

Δ 基金项目 江苏省药学会-恒瑞医院药学科研基金项目（No.
H202312） 国 际 癌 症 研 究 机 构 GLOBOCAN 2022 数 据 库
＊ 第一作者 主 管 药 师 。 研 究 方 向 ：临 床 药 学 。 E-mail： （https：//gco.iarc.who.int）的统计结果显示，2022 年全球
843742184@qq.com
新发肺癌病例数约为248.1万例，死亡病例数为181.7万
# 通信作者 主管药师，硕士。研究方向：临床药学。E-mail：
gongyinhua89@163.com 例，其发病率与死亡率均居全球恶性肿瘤首位；而我国

中国药房 2026年第37卷第5期 China Pharmacy 2026 Vol. 37 No. 5 · 655 ·